- Joined
- Nov 13, 2012
- Messages
- 121
- Reaction score
- 52
Appears to be Varian sweeping in and taking over everything...
Anyone have any experience with this VEP?
Shoot:
Anyone have any experience with this VEP?
Shoot:
They have gotten really tight on funding, and what little they give out only seems to go to long-term Varian yes-men.
I understand Siemens bought them so maybe that’s where the cost cuts are coming from.
Elekta can be very competitive on linac pricing but all of the other hassles that go with it still make varian the obvious choice for most clinicsVarian badly needs a competitor but Elekta just seems always a few years behind. Everything so clunky and two steps elekta to one step Varian to accomplish many tasks. From on board imaging to a treatment table to customer service, Elekta just in my experience can’t seem to step it up. We have both machines in our system and watching them head to head you can tell Elekta is behind.
I hope Elekta gets it together though, because Varian is getting worse in many ways (like this thread) with the money grabs. …their slant toward “renting” these treatment planning upgrade software algorithms seems…ugh.
Elekta is a funny company. They have put 100% of their efforts into the unity and just let the Versas languish. We have Versas at main and True Beams at our satellites and the difference is huge. But it doesn’t need to be. The lowest hanging fruit is the damn kV imager. Their abdominal and pelvic CBCTs are barely serviceable due to artifact susceptibility. You fix that one issue, the machines become a good bit more comparable (for the MD experience at least). But nope. They decided getting a gaiting system for the unity was more important. Now focused on other Unity upgrades.Varian badly needs a competitor but Elekta just seems always a few years behind. Everything so clunky and two steps elekta to one step Varian to accomplish many tasks. From on board imaging to a treatment table to customer service, Elekta just in my experience can’t seem to step it up. We have both machines in our system and watching them head to head you can tell Elekta is behind.
I hope Elekta gets it together though, because Varian is getting worse in many ways (like this thread) with the money grabs. …their slant toward “renting” these treatment planning upgrade software algorithms seems…ugh.
Agree completely. That’s been my experience.Elekta can be very competitive on linac pricing but all of the other hassles that go with it just still make varian the obvious choice for most clinics
Essentially a de facto monopoly
YES!Elekta is a funny company. They have put 100% of their efforts into the unity and just let the Versas languish. We have Versas at main and True Beams at our satellites and the difference is huge. But it doesn’t need to be. The lowest hanging fruit is the damn kV imager. Their abdominal and pelvic CBCTs are barely serviceable due to artifact susceptibility. You fix that one issue, the machines become a good bit more comparable (for the MD experience at least). But nope. They decided getting a fairing system for the unity was more important. Now focused on other Unity upgrades.
Now let’s talk business 101 here. If you have roughly 15% of their market share, the easiest path to growth is to expand your share. If you had to choose between an MR Linac or a VMAT/SBRT capable CT based machine maximize your market share, which one would you prioritize?
Elekta is basically running a monopoly with their MR-Linac. The only issue is, that data on superiority of MR-Linac over modern VMAT is still lacking. We only have a few trials that were run by Viewray and even those have ... debateable results.
Personally, I feel that adaptive treatment based on CBCT (as Varian already offers it) or CT (as Accuray is introducing it), will be a stronger selling argument and more easy to introduce into clinics.
None of this is data driven. Do you think the negative prostate proton trial will slow down proton expansion or stop places that have them from saying it’s a more precise treatment that can avoid their bowel better? I don’t.Elekta is basically running a monopoly with their MR-Linac. The only issue is, that data on superiority of MR-Linac over modern VMAT is still lacking. We only have a few trials that were run by Viewray and even those have ... debateable results.
Personally, I feel that adaptive treatment based on CBCT (as Varian already offers it) or CT (as Accuray is introducing it), will be a stronger selling argument and more easy to introduce into clinics.
Nearly my identical experience/thoughts. Make the imaging better and clean up the therapists interface/work flow/speed. The plans are fine and reliability/down time has been fine too.
YES.Add to that Monaco is a dumpster fire, offline image review in MOSAIQ is punitively slow, having to use a Hexapod bridge for 6Dof is archaic, and who decided to make the imaging panels fold IN?
I do like that they have 5mm MLCs through the entire field and it's nice that you can theoretically use the same collimator angle for arcs.
Exactly our calculus to stick with varian despite the much higher price tag.YES.
The hexapod bridge and really pushing everything into Monaco is an issue.
We are really happy with eclipse , so even though the price is right there is so much friction to even think about going more to Elekta when that also includes a change (for the worse IMO) on the planning side too.
Oh Monaco. This epitomizes my issues Elekta. Spend just a little bit of time with it, and you will begin asking yourself questions such as, did they include a single dosimetrist in the development process? We've been using it for the Unity for years and its a serviceable program once your whole team gets used to its "peculiarities". But it takes way longer than it should because so many things about its interface are just...odd.Add to that Monaco is a dumpster fire, offline image review in MOSAIQ is punitively slow, having to use a Hexapod bridge for 6Dof is archaic, and who decided to make the imaging panels fold IN?
I do like that they have 5mm MLCs through the entire field and it's nice that you can theoretically use the same collimator angle for arcs.